Amid a growing body of research on heart health devices and blood pressure monitoring, a new report from Blue Cross Blue Shield shows that women undergo fewer diagnostic procedures and treatments following a heart attack than men.
The National Institutes of Health called an early halt for an enormous, 9,300+ person trial examining the role of blood pressure intervention due to significant preliminary results. The U.S. agency found that maintaining systolic blood pressure at a lower level than current recommendations reduces rates of heart disease and the risk of death.
Infraredx will be acquired by its Japanese partner and investor Nipro. The pair had an exclusive 5-year distribution deal in Japan for the company to sell the startup's cardiac imaging system. Nipro has already gained Japanese approval for the NIRS-IVUS True Vessel Characterization Imaging System from Infraredx to find cholesterol-rich, lipid core coronary plaques that are thought to precipitate heart attack.
AstraZeneca's Brilinta can now be crushed and mixed with water or delivered through the nose via a tube, the FDA said, in a move designed to help patients who are unable to swallow the 90-mg tablets whole.
By switching on a protein in the heart, scientists may be able to improve recovery in patients that have just endured a heart attack.
A company based in Northern Ireland is advancing a rapid blood test to screen for a heart attack, allowing for doctors to more quickly treat affected patients. Randox Health's low-cost diagnostic has shown promise in early testing.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline's cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.
Philips Healthcare is touting some positive early results from a field study of its new hand-held blood test to spot patients at high risk for heart attacks or other "acute cardiac events."
In a study published in the journal Nature Materials, University of Pennsylvania scientists describe a hydrogel they developed that is designed to be applied directly to heart muscle to reduce continuing damage after a heart attack.